Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Mammary Carcinoma
100%
Neuroendocrine Breast Carcinoma
100%
Neuroendocrine Carcinoma
80%
Nuclear Grade
40%
Overall Survival
40%
Prognostic Factors
40%
Therapeutic Response
40%
Regional Lymph Node Metastasis
40%
Pathologic
20%
University of Texas
20%
Estrogen Receptor
20%
Cancer Center
20%
Tumor
20%
Demographic Characteristics
20%
Local Recurrence
20%
Radiation Therapy
20%
Tumor Size
20%
Clinical Features
20%
Therapeutic Outcome
20%
Distant Recurrence
20%
Improved Survival
20%
Stage at Presentation
20%
Statistical Power
20%
Progesterone Receptor
20%
Large Tumors
20%
Novel Therapeutics
20%
Treatment Outcome
20%
Response to Treatment
20%
Clinical Follow-up
20%
Patient Outcomes
20%
Pathological Features
20%
World Health Organization Classification
20%
Tumor Classification
20%
Clinical Entities
20%
Disease Stage
20%
Endocrine Therapy
20%
Therapeutic Benefits
20%
Distant Metastasis-free Survival
20%
Rare Type
20%
Aggressive Course
20%
Invasive Ductal Carcinoma
20%
Age-stage
20%
Human Epidermal Growth Factor Receptor 2-negative
20%
Case-controlled Study
20%
Invasive Mammary Carcinoma
20%
Medicine and Dentistry
Breast Carcinoma
100%
Neuroendocrine Carcinoma
100%
Neoplasm
22%
Treatment Response
22%
Overall Survival
22%
Prognostic Factor
22%
Lymph Node Metastasis
22%
Diseases
11%
Malignant Neoplasm
11%
Estrogen Receptor
11%
Radiation Therapy
11%
Epidermal Growth Factor Receptor 2
11%
Gamma Urogastrone
11%
Recurrent Disease
11%
Progesterone Receptor
11%
Clinical Feature
11%
Hormone Therapy
11%
Recurrence Free Survival
11%
Tumor
11%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Carcinoma
100%
Neuroendocrine Carcinoma
100%
Neoplasm
22%
Overall Survival
22%
Lymph Node Metastasis
22%
Diseases
11%
Malignant Neoplasm
11%
Recurrent Disease
11%
Estrogen Receptor
11%
Recurrence Free Survival
11%
Progesterone Receptor
11%
Endocrine Therapy
11%
Clinical Feature
11%
Epidermal Growth Factor Receptor 2
11%
Gamma Urogastrone
11%